Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Amniotic membrane transplantation in surgical treatment of conjunctival melanoma: long-term results

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Miscellaneous and Infections

Venue: Poster Village: Pod 3

First Author: : M.Palamar TURKEY

Co Author(s): :    B. Yaman   T. Akalin   A. Yagci        

Abstract Details

Purpose:

To investigate the long term efficacy and results of surgical management of conjunctival melanoma, reconstructed with amniotic membrane transplantation.

Setting:

Ege University Faculty of Medicine, Departments of Ophthalmology and Pathology

Methods:

Conjunctival melanoma in 10 patients (5 female, 5 male) was totally excised with adjunctional cryotherapy to the surgical margins, if cornea is involved corneal epitheliectomy with absolute alcohol, if episclera is involved lamellar sclerectomy and ocular surface grafting with cryopreserved amniotic membrane. Complications and tumor control rates were evaluated.

Results:

The mean age of the patients was 57.4 ± 15.2 (range, 37-84). The mean diameter of the tumors was 15.5 ± 4.9 (range, 10-25) mm and as confirmed with histopathology complete excision was performed in all cases. Mild limbal stem cell deficiency (2 eyes), and subclinic symblepharon (3 eyes) were detected as long term complications. In a mean follow-up of 56.7 ± 40.4 (range, 30-132) months only one local tumor recurrence was detected. Despite retreatment, exantheration was performed in this patient due to re-recurrence. One patient was deceased due to disceminated metastasis although there was no local recurrence.

Conclusions:

Especially in large conjunctival melanomas the reconstruction of the ocular surface is usually very hard. Cryopreserved amniotic membrane use for conjunctival defect repairment is safe and effective with mild complications to let surgeons to act courageously when excising the tumor tissue.

Financial Disclosure:

NONE

Back to previous